CROMSOURCE
, an international full service contract research organization (CRO) today announced the completion and opening of a new office building in Warsaw, Poland and the movement of key company services to this location.
‘Poland has been a key location for CROMSOURCE since our inception in 1994 ', noted Oriana Zerbini MD, Chief Executive Officer of CROMSOURCE. ‘We have a very large team in Poland which is a key country for delivery of our clinical projects. Our unique expertise in Poland and other Central and Eastern European countries provides our sponsors with the opportunity to complete their projects in a high quality, cost competitive and high enrolling environment. This is in large part due to the wide network of expert and committed investigators with whom CROMSOURCE has established a strong relationship based on mutual trust. I am delighted to announce that our long term project to continually develop our presence in Poland continues with the completed construction of our new offices in Warsaw and the relocation of our general company services there.’
Wanda Malkowska, Managing Director of CROMSOURCE sp. z o.o stated ‘In 2011 we rejected options to lease new premises and instead initiated a plan to invest in the construction of a new office building in Warsaw to accommodate our growing team in Poland. This project, which was entirely self-financed, has now been completed successfully and I can report that the move proceeded without any adverse impact on our operations or service to our clients.’
The new office is located in the Żoliborz district of Warsaw, only 4km (2.5 miles) from the city center and just 12km (7.5 miles) from Chopin airport. The office space is greater than 1000m2 (10,750 ft2) and incorporates a secure basement for archiving and storage. The building will house functions including Clinical Operations, Staffing Solutions, Human Resources Recrutiment & Selection, Accounting, Finance. This is also the location of Financial Service Center Unit that manages all invoicing, accounting and project administration activities for all Group entities following standardised procedures developed over many years.
About CROMSOURCE: CROMSOURCE is a high quality ISO-certified international provider of outsourced services to the pharmaceutical, biotechnology and medical device industries, specialized in clinical development and staffing solutions. CROMSOURCE was founded in 1994 and is unique in guaranteeing our clients that their trials will be delivered on time and within the contract price (our End-to-End guarantee).
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
March 11th 2025Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.